Cardiology

Restoring Blood Flow: Standard Treatments in the Acute Phase

At a Glance

Acute heart attack treatment focuses on restoring blood flow quickly. A STEMI is usually treated by opening the blocked artery with a thin tube and often a stent; clot-dissolving medicine may be used when this cannot happen promptly, while NSTEMI timing is based on risk.

The moments following a heart attack diagnosis are focused on one critical goal: reperfusion, or restoring the flow of oxygen-rich blood to your heart muscle. The clinical pathways for how this is done depend heavily on your ECG presentation (STEMI vs NSTEMI), your risk level, and the capabilities of the hospital you arrive at ^[1]^[2].

The Priority: STEMI Targets

If your ECG shows a STEMI, rapid intervention is a priority. Healthcare systems aim for specific “time-to-device” targets to minimize heart muscle injury ^[1].

Primary PCI (Stents)

The preferred treatment for an eligible STEMI is Primary PCI (Percutaneous Coronary Intervention). This involves using a catheter to physically open the blocked artery and usually placing a stent to keep it open ^[3].

Direct Arrival: If you arrive at a hospital with a cardiac catheterization lab (“cath lab”), the system target is to have the artery open within 90 minutes of your first contact with medical staff ^[1].
Transfer: If you are at a hospital without a cath lab, you should be transferred for PCI if the procedure can be performed within a 120-minute target window ^[4].

Fibrinolysis (The “Clot-Buster”)

If timely PCI cannot be achieved (outside the 120-minute window), eligible STEMI patients may receive fibrinolysis—powerful medications injected into a vein to dissolve the blood clot ^[5]. Clinicians will only use this after checking for major contraindications, such as a history of intracranial bleeding or current major bleeding risk.

The Follow-Up: Following fibrinolysis, standard practice involves transferring you to a PCI-capable center for an angiogram, typically within 2 to 24 hours ^[6]^[7].
Rescue PCI: If the medication fails to reopen the artery quickly, you will likely undergo an emergency “rescue” PCI ^[7].

The Risk-Stratified Approach: NSTEMI

For an NSTEMI, fibrinolysis is not the standard treatment. Instead, the timing of an angiogram and potential PCI is based on a risk-stratified strategy rather than a universal STEMI clock ^[8].

Risk Level	Clinical Presentation Framework	Timing Goal
Very High Risk	Shock, life-threatening arrhythmias, or chest pain that won’t go away despite treatment.	Immediate (<2 hours)
High Risk	Confirmed NSTEMI (dynamic troponin changes) or specific high-risk ECG patterns.	Early (<24 hours)
Low Risk	Stable symptoms, no major dynamic ECG changes, and lower calculated risk scores.	Selective (can be deferred or managed medically based on ongoing evaluation)

Note: These timing goals are frameworks. Hemodynamics, ongoing symptoms, kidney function, and bleeding risk can change the plan.

Inside the Cath Lab

While you are in the cath lab, the medical team uses specialized medications and techniques to ensure the procedure is safe.

Intraprocedural Anticoagulants: These are blood thinners given during the procedure to prevent clots from forming on the catheters. Unfractionated Heparin is common ^[9]. Another option, Bivalirudin, may be used to reduce serious bleeding risk in specific patients ^[10].
Radial Access: Most procedures now use the radial artery in the wrist rather than the femoral artery in the groin. Radial access is recommended because it significantly reduces the risk of major bleeding at the site of the incision ^[11]^[9].

This acute phase is about survival and stabilization. Once blood flow is restored and the immediate crisis is managed, your care shifts toward long-term recovery ^[12].

Common questions in this guide

What is the usual emergency treatment for a STEMI?

For an eligible STEMI, primary PCI is generally preferred. A thin catheter is used to open the blocked coronary artery, and a stent is often placed to help keep it open. If the patient arrives at a PCI-capable hospital, the system commonly aims to restore blood flow within 90 minutes of first medical contact.

When are clot-busting medicines used for a heart attack?

Fibrinolysis may be given to an eligible patient with STEMI when PCI cannot be performed within about 120 minutes. It is followed by transfer to a PCI-capable center for angiography, usually within 2 to 24 hours. If it does not reopen the artery promptly, rescue PCI may be needed.

How soon should someone with an NSTEMI have an angiogram?

Timing is based on risk rather than a single deadline. Very high-risk patients may need an angiogram immediately, within 2 hours; high-risk patients usually receive early angiography, within 24 hours; and stable lower-risk patients may have selective or deferred evaluation. Symptoms, circulation, kidney function, and bleeding risk can change the plan.

Why is the wrist often used for heart catheterization?

Radial access uses the artery in the wrist instead of the femoral artery in the groin. It is commonly recommended because it lowers the risk of major bleeding at the access site. The best route depends on the patient's anatomy, condition, and the procedure.

What blood thinners are used during PCI?

Unfractionated heparin is commonly used during PCI, and bivalirudin may be considered in selected patients, especially when reducing serious bleeding is a concern. The medical team chooses the medication based on the procedure and the patient's bleeding risk.

Curated prompts to bring to your next appointment.

1.Was my procedure considered 'primary PCI,' and how long was the time from my first medical contact to the stent being placed?
2.For my NSTEMI, was I classified as 'very high risk' or 'high risk' to determine the timing of my angiogram?
3.If I received 'clot-busting' medication (fibrinolysis), was my heart successfully reopened, or was a 'rescue PCI' needed?
4.Which anticoagulant was used during my procedure, and were there any concerns about my bleeding risk?
5.Was the catheter inserted through my wrist (radial access) or my groin (femoral access), and why?
6.Based on the guidelines, did I receive a 'risk-stratified' invasive strategy for my specific presentation?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (12)

1
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Rao SV, O'Donoghue ML, Ruel M, et al.
Journal of the American College of Cardiology 2025; (85(22)):2135-2237 doi:10.1016/j.jacc.2024.11.009.
PMID: 40013746
2
Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies-a review.
Scheldeman L, Sinnaeve P, Albers GW, et al.
European heart journal 2024; (45(30)):2735-2747 doi:10.1093/eurheartj/ehae371.
PMID: 38941344
3
From Q/Non-Q Myocardial Infarction to STEMI/NSTEMI: Why It's Time to Consider Another Simplified Dichotomy; a Narrative Literature Review.
Avdikos G, Michas G, Smith SW
Archives of academic emergency medicine 2022; (10(1)) doi:10.22037/aaem.v10i1.1783.
PMID: 36426169
4
Nationwide Analysis of Patients With ST-Segment-Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention: Findings From the American Heart Association Mission: Lifeline Program.
Dauerman HL, Bates ER, Kontos MC, et al.
Circulation. Cardiovascular interventions 2015; (8(5)).
PMID: 25901044
5
Rural and Remote Acute STEMI Diagnosis and Management: Current Status and Future Directions.
Gadeley R, Arnold R, Amos D, et al.
Heart, lung & circulation 2025; (34(12)):1332-1343 doi:10.1016/j.hlc.2025.06.1035.
PMID: 40897570
6
STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial.
Van de Werf F, Ristić AD, Averkov OV, et al.
Circulation 2023; (148(9)):753-764 doi:10.1161/CIRCULATIONAHA.123.064521.
PMID: 37439219
7
Fibrinolytic Therapy in Patients with Acute ST-elevation Myocardial Infarction.
Krittanawong C, Hahn J, Kayani W, Jneid H
Interventional cardiology clinics 2021; (10(3)):381-390 doi:10.1016/j.iccl.2021.03.011.
PMID: 34053624
8
Immediate and early percutaneous coronary intervention in very high-risk and high-risk non-ST segment elevation myocardial infarction patients.
Lupu L, Taha L, Banai A, et al.
Clinical cardiology 2022; (45(4)):359-369 doi:10.1002/clc.23781.
PMID: 35266561
9
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.
Erlinge D, Omerovic E, Fröbert O, et al.
The New England journal of medicine 2017; (377(12)):1132-1142 doi:10.1056/NEJMoa1706443.
PMID: 28844201
10
Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography).
Clemmensen P, Wiberg S, Van't Hof A, et al.
JACC. Cardiovascular interventions 2015; (8(1 Pt B)):214-220 doi:10.1016/j.jcin.2014.11.002.
PMID: 25616927
11
Transradial Approach in Primary Percutaneous Coronary Intervention: Lessons from a High-volume Centre.
Piers LH, Vink MA, Amoroso G
Interventional cardiology (London, England) 2016; (11(2)):88-92 doi:10.15420/icr.2016:21:3.
PMID: 29588712
12
Antithrombotic treatment in primary percutaneous coronary intervention.
Voll F, Kuna C, Ndrepepa G, et al.
Expert review of cardiovascular therapy 2021; (19(4)):313-324 doi:10.1080/14779072.2021.1902807.
PMID: 33705211

This page is for informational purposes only and does not constitute medical advice. If you may be having a heart attack, call emergency services rather than relying on this information.

Get notified when new evidence is published on acute myocardial infarction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents